CEO: Nigel Davis, PhD, MBA. Dr Davis has been commercialising technology for more than 24 years, with experience in biotech management and business development. His previous positions include Glaxo, Innovir, ISIS Innovation and PharmaVentures and NED at Ploughshare Innovations.
CSO: Prof Ivan Roitt FRS, Co-founder and co-inventor of NALIA technology. He is head of Cancer Research Institute at Middlesex University and previously Head of Departments of Immunology & Rheumatology Research at University College London. Prof. Rovit has 280 publications to his name, and is a pioneer in the research of autoimmune diseases.
Chairman: Graham Hine. Graham acted as lead investor for NALIA’s recent oversubscribed fundraising through Syndicate Room. He is a highly successful technology entrepreneur with a track record in leading, growing and successfully exiting technology companies through both trade sale and flotation. He began his career with Philips and has subsequently gained over 20 years’ CEO and Chairman experience, at companies including Capteur Sensors, P2i, Hardide and SGX Sensortech. Graham is currently Chairman of several technology companies.
Technical Director: Berwyn Clarke, PhD. Dr Clarke has been working in the pharmaceutical and diagnostics industries for over 25 years. His experience includes both global business such as GlaxoWellcome and Bayer Diagnostics, and small start-up companies.
Non-executive director: Ian Armitage. Ian is a highly experienced patent attorney, having worked at Mewburn Ellis for over 40 years, as well as in the pharmaceutical and biotechnology industry sectors. He has considerable expertise in EPO opposition and appeal proceedings with a reputation for successfully tackling complex legal problems in genetic engineering and biotechnology opposition/appeal cases. Ian has known NALIA for some time and was a major investor in the recent funding round.
COO: Marcus Harrison. Marcus has a background in diagnostic product development and service provision. He acted as Head of Technical Programmes, Head of Computational Biology and Head of Services at Oxford Gene Technology. He also held the position of Chief Scientific Officer and Board Director at Mediwatch where he led projects across the full product life-cycle, including co-ordinating clinical trials and securing regulatory approval in both the US and Europe for novel diagnostic products.
Principal Scientist: Yuliya Yatsenko, PhD, has several years of experience with NALIA technology and the design and testing of multiplex immunoassay biomarker arrays.
Clinical Advisor: Prof Ian Cree is co-founder and co-inventor of NALIA technology. He is a consultant pathologist to University Hospitals Coventry and Warwickshire and leads a clinical diagnostic laboratory service, and Professor of Pathology at the University of Warwick; he sits on numerous clinical and diagnostic committees and is an expert in the clinical adoption of new IVD tests.